Thank you for your email and interest in ENDRA Life Sciences.
As you know, the company does not control the stock’s trading activity, and the best way to address the stock’s performance is for the business to perform. Management is committed to executing its business strategy to commercialize the TAEUS system and looks forward to updating shareholders on material developments as appropriate.
As management stated in the last earnings conference call, there are several key milestones the company is striving to achieve this year including:
Advancing TAEUS through the US regulatory process and submitting a De Novo request,
Demonstrating TAEUS' clinical value by generating additional data with its evaluation sites to support its regulatory submission and commercialization,
Accelerating its commercial channel and marketing activities in line with the reopening of global markets to generate orders for TAEUS in Europe,
Securing additional pharmaceutical and other industry partnerships to expand the opportunity for TAEUS outside the clinical end-user market and
Continuing to strengthen its intellectual property portfolio to protect its proprietary technology, expand its potential area of use and increase out licensing opportunities.
Kind regards,
Yvonne
News 
Market Data 
Discover 
